Danielle DiTirro PhD

Joined Merck in 2022 and provides scientific and regulatory support for biosafety testing and characterization of biologic therapeutics, with a specialty in cell and gene therapies. Before joining Merck, Dirtirro held roles guiding assay development efforts for vaccines, cell therapies, and gene therapies, focusing on quality control and diagnostic applications. Ditirro received her PhD in molecular and cellular biology from Brandeis University.